AL-ADTRAN
25.3.2024 14:01:34 CET | Business Wire | Press release
Adtran and Vertilas today announced the industry’s first 100Gbit/s PAM4 single-mode vertical-cavity surface-emitting laser (VCSEL) technology with capabilities up to 1.6Tbit/s. On display at this week’s OFC, it sets new standards for low power consumption in optical engines and modules, with up to 80% reduction in power on the transmit optics compared to conventional solutions. Tailored specifically for the rigorous demands of intra-data center operations and AI/ML workloads, Adtran’s latest offering achieves unprecedented efficiency, consuming less than 2pJ/bit, including the laser driver. This significantly undercuts current industry standards, including those cited by co-packaged optics. The advancement is set to extend the capabilities of Adtran’s MicroMux™ family of small-form-factor pluggable transceivers. A major step towards meeting the needs of the rapidly expanding generative AI application market, Adtran’s latest innovation addresses the growing demand for robust, high-capacity and environmentally friendly data processing solutions.
“As the importance of data volume and speed escalates, the demand for increased bandwidth and enhanced energy efficiency accelerates. Our introduction of the market’s first 100Gbit/s PAM4 single-mode VCSEL technology, scalable to 1.6Tbit/s, epitomizes our proactive approach to tackling these emerging requirements. By pushing the limits of speed and significantly reducing power consumption, we’re creating tomorrow’s benchmarks,” said Ross Saunders, GM of optical engines at Adtran. “Our new technology promises to significantly improve intra-data center connectivity and AI application efficiencies, merging high performance with long-term sustainability. As we prepare for the leap towards 800Gbit/s and 1.6Tbit/s applications, we’re enhancing the foundations of efficient, high-capacity data ecosystems worldwide.”
Building on the success of Adtran’s MicroMux™ family, the new VCSEL technology leverages a short-cavity single-mode design and is based on indium phosphide semiconductor material. This enables it to operate across both O-band and C-band wavelengths, delivering 100Gbit/s per channel. By stacking multiple single-mode lasers into arrays, this approach achieves throughput of 800Gbit/s and 1.6Tbit/s, ensuring superior performance with a significant reduction in power consumption and costs. This enhanced energy efficiency presents a major advantage for IP router and Ethernet switch faceplate density. What’s more, its versatility extends to supporting a wide array of applications from DR4/8/16 to various FR4 links within optical engines, all while maintaining power consumption below 200mW per lane.
“As applications such as generative AI proliferate and enterprises expand their AI clusters, the need for advanced optical interconnects capable of supporting Terabit connectivity has reached a critical juncture. Our 100Gbit/s PAM4 single-mode VCSEL technology meets this challenge head-on. It enables energy efficiency and the capacity for higher-density deployments while at the same time addressing manufacturing, testing and assembly costs,” commented Christoph Glingener, CTO of Adtran. “This technology supports throughput of up to 800Gbit/s and 1.6Tbit/s, significantly reducing operational expenses while enhancing network capabilities. Our approach underscores a commitment to delivering sustainable, high-capacity networking solutions that break through existing barriers, readying networks for the next wave of AI infrastructure development.”
Demos of Adtran’s new VCSEL technology are available at this week’s OFC on request.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240322173283/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
